Cohance Lifesciences · NSE: COHANCE · BSE: 543064
Q4 FY25 results · Jan–Mar 2025
Cohance Lifesciences reported revenue from operations of ₹402.02 crore (up 58.9% from Q4 FY24) and net profit of ₹38.73 crore (down 27.4% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 402.02 | 252.93 | +58.9% | 307.15 | +30.9% |
| Other income | 10.57 | 17.05 | −38.0% | 15.71 | −32.7% |
| Total income | 412.59 | 269.98 | +52.8% | 322.86 | +27.8% |
| Profit before tax | 51.60 | 70.85 | −27.2% | 109.73 | −53.0% |
| Net profit for the period | 38.73 | 53.37 | −27.4% | 83.29 | −53.5% |
| Attributable to shareholders of the company | 42.01 | — | — | 82.88 | −49.3% |
| EPS, basic (₹) | 1.65 | 2.10 | −21.3% | 3.26 | −49.3% |
| Net margin (%) | 9.6 | 21.1 | 27.1 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 330.17 | 243.52 | +35.6% | 275.39 | +19.9% |
| Other income | 6.63 | 16.87 | −60.7% | 15.18 | −56.3% |
| Total income | 336.80 | 260.39 | +29.3% | 290.57 | +15.9% |
| Profit before tax | 56.32 | 71.06 | −20.7% | 114.60 | −50.9% |
| Net profit for the period | 44.34 | 53.43 | −17.0% | 86.35 | −48.7% |
| EPS, basic (₹) | 1.74 | 2.10 | −17.1% | 3.39 | −48.7% |
| Net margin (%) | 13.4 | 21.9 | 31.4 |
Consolidated
- Filed with BSE
- 28 May 2025, 21:34 IST
- Board meeting
- 28 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 28 May 2025, 21:34 IST
- Board meeting
- 28 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE